

## 10-Year Financial/Non-financial Data (For the fiscal years as of/ended March 31)

(Millions of yen)

	JGAAP						IFRS				
	2012	2013	2014	2015	2016	2017	2017	2018	2019	2020*	2021**
<b>Revenue</b>	848,548	743,851	713,286	764,671	804,578	748,050	740,557	786,497	793,862	755,231	730,544
<b>Selling, general and administrative (SG&amp;A) expenses</b>	348,287	343,121	367,011	398,889	430,773	414,855	397,697	426,596	437,510	381,171	357,032
Percentage of revenue (%)	41.0%	46.1%	51.5%	52.2%	53.5%	55.5%	53.7%	54.2%	55.1%	50.5%	48.9%
<b>Operating profit</b>	35,518	35,077	73,445	90,962	104,464	76,487	71,192	81,029	28,281	92,200	81,985
Percentage of revenue (%)	4.2%	4.7%	10.3%	11.9%	13.0%	10.2%	9.6%	10.3%	3.6%	12.2%	11.2%
<b>Profit (loss) before tax</b>	(9,495)	19,142	16,425	8,934	70,800	81,686	62,481	76,665	20,117	86,617	76,810
<b>Net income (loss) (JGAAP)/Profit (loss) attributable to owners of parent (IFRS)</b>	(48,985)	8,020	13,627	(8,737)	62,594	78,191	42,783	57,064	8,147	51,670	12,918
Percentage of revenue (%)	—	1.1%	1.9%	—	7.8%	10.5%	5.8%	7.3%	1.0%	6.8%	1.8%
<b>EBITDA margin*1 (%)</b>	9.5%	10.6%	16.8%	18.5%	19.2%	17.4%	16.9%	17.0%	11.0%	21.1%	19.4%
EBITDA margin (Medical Business)**2 (%)	26.6%	29.0%	29.7%	29.1%	29.5%	27.4%	27.4%	26.5%	24.9%	29.3%	27.7%
<b>R&amp;D expenditures</b>	61,356	63,379	66,796	74,101	81,415	79,178	79,178	89,469	93,968	87,750	81,794
Percentage of revenue (%)	7.2%	8.5%	9.4%	9.7%	10.1%	10.6%	10.7%	11.4%	11.8%	11.6%	11.2%
<b>Capital expenditures</b>	37,961	28,109	37,810	47,743	64,445	49,347	60,683	65,255	66,830	74,673	98,935
<b>Depreciation and amortization</b>	33,787	33,899	36,850	41,219	39,912	44,658	54,290	52,913	58,669	67,377	59,559
<b>Amortization of goodwill</b>	11,103	9,683	9,457	9,421	9,867	8,642	—	—	—	—	—
<b>Financial indicators</b>											
Total assets*3	966,526	960,239	1,027,475	1,081,551	1,000,614	991,062	960,032	978,663	932,030	1,015,663	1,181,017
Total net assets (JGAAP)*3/Total equity (IFRS)	48,028	151,907	331,284	357,254	384,283	430,880	396,228	444,259	442,387	371,958	395,480
Equity ratio (JGAAP)/Ratio of equity attributable to owners of parent to total assets (IFRS) (%)	4.6%	15.5%	32.1%	32.9%	38.2%	43.3%	41.1%	45.2%	47.3%	36.5%	33.4%
Interest-bearing debt	642,426	560,390	415,831	354,421	321,138	286,357	285,970	247,974	181,335	280,915	355,264
Net debt	442,338	330,780	163,710	144,546	154,584	86,926	86,505	56,735	66,909	118,421	137,786
Inventories	102,493	99,307	98,595	107,387	111,558	124,064	125,319	139,309	153,623	167,596	158,984
Inventory turnover period*4 (months)	1.4	1.6	1.7	1.6	1.6	1.9	1.9	2.0	2.2	2.6	2.7
Cash and cash equivalents at end of year	198,661	225,782	251,344	209,809	166,323	199,431	199,465	191,239	114,563	162,494	217,478
Cash flows from operating activities	30,889	25,233	72,388	66,811	48,621	90,194	102,052	95,146	66,943	133,544	124,122
Cash flows from investing activities	(35,735)	33,455	(20,273)	(39,612)	(52,897)	(8,305)	(20,814)	(53,312)	(60,296)	(62,430)	(118,918)
Cash flows from financing activities	(5,761)	(42,436)	(39,693)	(70,185)	(33,870)	(44,244)	(43,615)	(51,058)	(82,948)	(19,462)	40,800
Return on equity (ROE) (%)	(62.3)%	8.3%	5.7%	(2.6)%	17.0%	19.3%	11.3%	13.6%	1.8%	12.7%	3.4%
Return on assets (ROA) (%)	(4.9)%	0.8%	1.4%	(0.8)%	6.0%	7.9%	4.4%	5.9%	0.9%	5.3%	1.2%
Net income (loss) per share*5 (JGAAP)/ Profit attributable to owners of parent per share (IFRS) (yen)	(183.54)	28.96	41.05	(25.53)	182.90	228.47	125.01	41.71	5.97	39.37	10.05
Total equity per share*5 (JGAAP)/ Equity attributable to owners of parent per share (IFRS) (yen)	167.76	493.30	962.83	1,038.64	1,117.24	1,252.96	1,153.45	324.25	323.06	288.39	306.72
Price earnings ratio (PER)*6 (times)	—	76.4	80.2	—	23.9	18.7	34.2	24.2	201.3	39.7	228.0
Price book-value ratio (PBR) (times)	8.1	4.5	3.4	4.3	3.9	3.4	3.7	3.1	3.7	5.4	7.5
Outstanding market value (billions of yen)	367.3	675.8	1,127.4	1,530.0	1,499.2	1,466.6	1,466.6	1,384.5	1,647.8	2,141.4	3,140.8
Cash dividends per share*7 (yen)	—	—	—	2.5	4.25	7	7	7	7.5	10	12
<b>Average exchange rate</b>											
U.S. dollar/Yen	79.08	83.10	100.24	109.93	120.14	108.38	108.38	110.85	110.91	108.74	106.06
Euro/Yen	108.98	107.14	134.37	138.77	132.58	118.79	118.79	129.70	128.41	120.82	123.70
<b>Non-financial indicators</b>											
Number of employees	34,112	30,697	30,702	31,540	33,336	34,687	34,687	35,933	35,124	35,174	31,653
[Average number of temporary employees]	[5,009]	[2,240]	[2,978]	[1,374]	[1,257]	[1,298]	[1,298]	[1,511]	[1,396]	[1,437]	[1,135]
Overseas employees as a percentage of employees (%)	62.1%	62.4%	62.5%	63.2%	63.3%	63.7%	63.7%	63.7%	61.9%	61.3%	57.2%
Percentage of women in management roles in Japan*9 (%)	0.8%	0.9%	1.0%	1.2%	1.4%	1.9%	1.9%	2.3%	2.9%	3.2%	3.5%
Percentage of women in management roles globally*10 (%)	—	—	—	—	—	—	—	—	—	8.4%	10.8%
Percentage of foreign management roles globally*10 (%)	—	—	—	—	—	—	—	—	—	32.2%	36.9%
Percentage of employees with disabilities*11 (%)	1.9%	1.9%	2.0%	2.1%	1.9%	2.1%	2.1%	2.2%	2.2%	2.3%	2.6%

\*1 At the Company, EBITDA is calculated using the following assumptions: EBITDA = Operating profit + Depreciation and amortization that is included in cost of sales or SG&A expenses + Amortization of goodwill that is included in SG&A expenses  
EBITDA margin = EBITDA / Revenue

\*2 At the Company, EBITDA (Medical Business) is calculated using the following assumptions: EBITDA = Segment profit in the Medical Business + Depreciation and amortization that is included in cost of sales or SG&A expenses + Amortization of goodwill that is included in SG&A expenses  
EBITDA margin (Medical Business) = EBITDA (Medical Business) / Revenue

\*3 In line with the issuance of IAS No. 19 "Employee Benefits" (revised on June 16, 2011) to be applied for fiscal years beginning on or after January 1, 2013, certain overseas subsidiaries adopted IAS No. 19 effective from the fiscal year ended March 31, 2014, and changed their method of recognizing actuarial gain or loss. This change has been applied retroactively to the March 31, 2013.

\*4 The revenue used to calculate the inventory turnover period for fiscal year 2020 is for continuing operations only.

\*5 The Company conducted a stock split at the ratio of four shares for one ordinary share on April 1, 2019. "Profit attributable to owners of parent per share" is expressed with the figure after the stock split. The figure for the fiscal year ended March 31, 2019 is recalculated using the same method.

\*6 Price earnings ratio (PER) for the fiscal years ended March 31, 2012 and 2015 are omitted as the Company recorded net loss for these fiscal years.

\*7 The Company conducted a stock split at the ratio of four shares for one ordinary share on April 1, 2019. Figures prior to the year ended March 31, 2019 have been converted to align with the post-stock split standard.

\*8 From the second quarter of fiscal year 2021, the Imaging Business has been categorized as a discontinued operation. Accordingly, we restated figures for fiscal year 2020.

\*9 Figures for fiscal year 2020 are for Olympus Corporation as of the end of March, and those for the Olympus Group in Japan as of April 1 for fiscal year 2021.

\*10 The percentage within global senior management as of August 1, 2020 for fiscal year 2020 and July 1, 2021 for fiscal year 2021.

\*11 Through fiscal year 2019, figures are as of June 1 of each respective year, and from fiscal year 2020, the figures are as of March 31 of each respective year for individuals in Japan (at eight special-purpose subsidiaries).